193 results on '"Gandaglia G"'
Search Results
2. Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives
- Author
-
Kretschmer, A., van den Bergh, RCN, Martini, A., Marra, G., Valerio, M., Tsaur, I., Heidegger, I., Kasivisvanathan, V., Kesch, C., Preisser, F., Fankhauser, C.D., Zattoni, F., Ceci, F., Olivier, J., Chiu, P., Puche-Sanz, I., Thibault, C., Gandaglia, G., Tilki, D., and On Behalf Of The Yau Prostate Cancer Working Group
- Subjects
EQ-5D ,FACT-P ,QLQ-C30 ,health-related quality of life ,metastatic ,prostate cancer - Abstract
With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.
- Published
- 2021
3. Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer
- Author
-
Surcel C., Mirvald C., Tsaur I., Borgmann H., Heidegger I., Labanaris A. P., Sinescu I., Tilki D., Ploussard G., Briganti A., Montorsi F., Mathieu R., Valerio M., Jinga V., Badescu D., Radavoi D., van den Bergh R. C. N., Gandaglia G., Kretschmer A., Surcel, C., Mirvald, C., Tsaur, I., Borgmann, H., Heidegger, I., Labanaris, A. P., Sinescu, I., Tilki, D., Ploussard, G., Briganti, A., Montorsi, F., Mathieu, R., Valerio, M., Jinga, V., Badescu, D., Radavoi, D., van den Bergh, R. C. N., Gandaglia, G., and Kretschmer, A.
- Subjects
Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Symptomatic ,Cystectomy ,Cystoprostatectomy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,medicine ,Humans ,Neoplasm Invasiveness ,Survival analysis ,Aged ,Neoplasm Staging ,Retrospective Studies ,Prostatectomy ,Palliative ,Pelvic exenteration ,business.industry ,Proportional hazards model ,Rectal Neoplasms ,Advanced prostate cancer ,Urinary diversion ,Palliative Care ,Prostatic Neoplasms ,Perioperative ,Middle Aged ,medicine.disease ,Surgery ,Pelvic Exenteration ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Feasibility Studies ,business - Abstract
Objective: To access the feasibility of palliative cystoprostatectomy/pelvic exenteration in patients with bladder/rectal invasion due to prostate cancer (PC). Patients and methods: Twenty-five men with cT4 PC were retrospectively identified in the institutional databases of six tertiary referral centers in the last decade. Local invasion was documented by CT or MRI scans and was confirmed by urethrocystoscopy. Oncological therapies, local symptoms, previous local treatments, time from diagnosis to intervention and type of surgical procedure were recorded. Patients were divided into groups: ADT group (12 pts) and 13 pts without any history of previous local/systemic treatments for PCa (nonADT groups). Perioperative complications were classified using the Clavien–Dindo system. Overall survival (OS) was defined as the time from surgery to death from any cause. A Cox regression analysis, stratified for ISUP score and previous hormonal treatment (ADT) was also performed for survival analysis. Results: Ileal conduit was the main urinary diversion in both cohorts. For the entire cohort, complication rate was 44%. No significant differences regarding perioperative complications and complication severity between both subgroups were observed (p = 0.2). Median follow-up was 15months (range 3–41) for the entire cohort with a median survival of 15months (95% CI 10.1–19.9). In Cox regression analysis stratified for ISUP score, no statistically significant differences in OS in patients with and without previous ADT before cystectomy or exenteration were observed (HR 3.26, 95% CI 0.62–17.23, p = 0.164). Conclusion: Palliative cystoprostatectomy and pelvic exenteration represent viable treatment options associated with acceptable morbidity and good short-term survival outcome.
- Published
- 2021
4. Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate
- Author
-
Schiffmann, J., Tennstedt, P., Fischer, J., Tian, Zhe, Beyer, B., Boehm, K., Sun, M., Gandaglia, G., Michl, U., Graefen, M., and Salomon, G.
- Published
- 2014
- Full Text
- View/download PDF
5. Introducing PIONEER: a project to harness big data in prostate cancer research
- Author
-
Omar M. I., Roobol M. J., Ribal M. J., Abbott T., Agapow P. -M., Araujo S., Asiimwe A., Auffray C., Balaur I., Beyer K., Bernini C., Bjartell A., Briganti A., Butler-Ransohoff J. -E., Campi R., Cavelaars M., De Meulder B., Devecseri Z., Voss M. D., Dimitropoulos K., Evans-Axelsson S., Franks B., Fullwood L., Horgan D., Smith E. J., Kiran A., Kivinummi K., Lambrecht M., Lancet D., Lindgren P., MacLennan S., Nogueira M. M., Moen F., Moinat M., Papineni K., Reich C., Reiche K., Rogiers S., Sartini C., van Bochove K., van Diggelen F., Van Hemelrijck M., Van Poppel H., Zong J., N'Dow J., Andersson E., Arala H., Auvinen A., Bangma C., Burke D., Cardone A., Casariego J., Cuperus G., Dabestani S., Esperto F., Fossati N., Fridhammar A., Gandaglia G., Tandefelt D. G., Horn F., Huber J., Hugosson J., Huisman H., Josefsson A., Kilkku O., Kreuz M., Lardas M., Lawson J., Lefresne F., Lejeune S., Longden-Chapman E., McVie G., Moris L., Mottet N., Murtola T., Nicholls C., Pang K. H., Pascoe K., Picozzi M., Plass K., Pohjanjousi P., Reaney M., Remmers S., Robinson P., Schalken J., Schravendeel M., Seisen T., Servan A., Shiranov K., Snijder R., Steinbeisser C., Taibi N., Talala K., Tilki D., Van den Broeck T., Vassilev Z., Voima O., Vradi E., Waldeck R., Weistra W., Willemse P. -P., Wirth M., Wolfinger R., Kermani N. Z., Omar, M. I., Roobol, M. J., Ribal, M. J., Abbott, T., Agapow, P. -M., Araujo, S., Asiimwe, A., Auffray, C., Balaur, I., Beyer, K., Bernini, C., Bjartell, A., Briganti, A., Butler-Ransohoff, J. -E., Campi, R., Cavelaars, M., De Meulder, B., Devecseri, Z., Voss, M. D., Dimitropoulos, K., Evans-Axelsson, S., Franks, B., Fullwood, L., Horgan, D., Smith, E. J., Kiran, A., Kivinummi, K., Lambrecht, M., Lancet, D., Lindgren, P., Maclennan, S., Nogueira, M. M., Moen, F., Moinat, M., Papineni, K., Reich, C., Reiche, K., Rogiers, S., Sartini, C., van Bochove, K., van Diggelen, F., Van Hemelrijck, M., Van Poppel, H., Zong, J., N'Dow, J., Andersson, E., Arala, H., Auvinen, A., Bangma, C., Burke, D., Cardone, A., Casariego, J., Cuperus, G., Dabestani, S., Esperto, F., Fossati, N., Fridhammar, A., Gandaglia, G., Tandefelt, D. G., Horn, F., Huber, J., Hugosson, J., Huisman, H., Josefsson, A., Kilkku, O., Kreuz, M., Lardas, M., Lawson, J., Lefresne, F., Lejeune, S., Longden-Chapman, E., Mcvie, G., Moris, L., Mottet, N., Murtola, T., Nicholls, C., Pang, K. H., Pascoe, K., Picozzi, M., Plass, K., Pohjanjousi, P., Reaney, M., Remmers, S., Robinson, P., Schalken, J., Schravendeel, M., Seisen, T., Servan, A., Shiranov, K., Snijder, R., Steinbeisser, C., Taibi, N., Talala, K., Tilki, D., Van den Broeck, T., Vassilev, Z., Voima, O., Vradi, E., Waldeck, R., Weistra, W., Willemse, P. -P., Wirth, M., Wolfinger, R., Kermani, N. Z., Publica, and Urology
- Subjects
0301 basic medicine ,Prioritization ,Knowledge management ,Urology ,media_common.quotation_subject ,education ,Big data ,Disease ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Multidisciplinary approach ,Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] ,Medicine ,Quality (business) ,media_common ,business.industry ,Patient-centered outcomes ,medicine.disease ,3. Good health ,Patient management ,030104 developmental biology ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,030220 oncology & carcinogenesis ,business - Abstract
Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide.Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. In this Perspectives article, the authors introduce the PIONEER project and describe its aims and plans for ultimately improving prostate cancer care through the use of big data.
- Published
- 2020
6. Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?
- Author
-
Zattoni, F., Heidegger, I., Kasivisvanathan, V., Kretschmer, A., Marra, G., Magli, A., Preisser, F., Tilki, D., Tsaur, I., Valerio, M., van den Bergh, R., Kesch, C., Ceci, F., Fankhauser, C., and Gandaglia, G.
- Subjects
adjuvant radiotherapy ,biochemical recurrence ,genomic classifiers ,hormonal therapy ,prostate cancer ,salvage radiotherapy - Abstract
The role and timing of radiotherapy (RT) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) remains controversial. While recent trials support the oncological safety of early salvage RT (SRT) compared to adjuvant RT (ART) in selected patients, previous randomized studies demonstrated that ART might improve recurrence-free survival in patients at high risk for local recurrence based on adverse pathology. Although ART might improve survival, this approach is characterized by a risk of overtreatment in up to 40% of cases. SRT is defined as the administration of RT to the prostatic bed and to the surrounding tissues in the patient with PSA recurrence after surgery but no evidence of distant metastatic disease. The delivery of salvage therapies exclusively in men who experience biochemical recurrence (BCR) has the potential advantage of reducing the risk of side effects without theoretically compromising outcomes. However, how to select patients at risk of progression who are more likely to benefit from a more aggressive treatment after RP, the exact timing of RT after RP, and the use of hormone therapy and its duration at the time of RT are still open issues. Moreover, what the role of novel imaging techniques and genomic classifiers are in identifying the most optimal post-operative management of PCa patients treated with RP is yet to be clarified. This narrative review summarizes most relevant published data to guide a multidisciplinary team in selecting appropriate candidates for post-prostatectomy radiation therapy.
- Published
- 2021
7. Radical Prostatectomy: Sequelae in the Course of Time
- Author
-
Kesch, C., Heidegger, I., Kasivisvanathan, V., Kretschmer, A., Marra, G., Preisser, F., Tilki, D., Tsaur, I., Valerio, M., van den Bergh, RCN, Fankhauser, C.D., Zattoni, F., and Gandaglia, G.
- Subjects
adverse (side) effects ,long-term outcome ,prostate cancer ,retropubic radical prostatectomy ,robot-assisted radical prostatectomy - Abstract
Objective: Radical prostatectomy (RP) is a frequent treatment for men suffering from localized prostate cancer (PCa). Whilst offering a high chance for cure, it does not come without a significant impact on health-related quality of life. Herein we review the common adverse effects RP may have over the course of time. Methods: A collaborative narrative review was performed with the identification of the principal studies on the topic. The search was executed by a relevant term search on PubMed from 2010 to February 2021. Results: Rates of major complications in patients undergoing RP are generally low. The main adverse effects are erectile dysfunction varying from 11 to 87% and urinary incontinence varying from 0 to 87% with a peak in functional decline shortly after surgery, and dependent on definitions. Different less frequent side effects also need to be taken into account. The highest rate of recovery is seen within the first year after RP, but even long-term improvements are possible. Nevertheless, for some men these adverse effects are long lasting and different, less frequent side effects also need to be taken into account. Despite many technical advances over the last two decades no surgical approach can be clearly favored when looking at long-term outcome, as surgical volume and experience as well as individual patient characteristics are still the most influential variables. Conclusions: The frequency of erectile function and urinary continence side effects after RP, and the trajectory of recovery, need to be taken into account when counseling patients about their treatment options for prostate cancer.
- Published
- 2021
8. Focal Therapy for Prostate Cancer: Complications and Their Treatment
- Author
-
Rakauskas, A., Marra, G., Heidegger, I., Kasivisvanathan, V., Kretschmer, A., Zattoni, F., Preisser, F., Tilki, D., Tsaur, I., van den Bergh, R., Kesch, C., Ceci, F., Fankhauser, C., Gandaglia, G., and Valerio, M.
- Subjects
HIFU ,complications ,cryotherapy ,focal therapy ,photodynamic therapy ,prostate cancer - Abstract
Focal therapy is a modern alternative to selectively treat a specific part of the prostate harboring clinically significant disease while preserving the rest of the gland. The aim of this therapeutic approach is to retain the oncological benefit of active treatment and to minimize the side-effects of common radical treatments. The oncological effectiveness of focal therapy is yet to be proven in long-term robust trials. In contrast, the toxicity profile is well-established in randomized controlled trials and multiple robust prospective cohort studies. This narrative review summarizes the relevant evidence on complications and their management after focal therapy. When compared to whole gland treatments, focal therapy provides a substantial benefit in terms of adverse events reduction and preservation of genito-urinary function. The most common complications occur in the peri-operative period. Urinary tract infection and acute urinary retention can occur in up to 17% of patients, while dysuria and haematuria are more common. Urinary incontinence following focal therapy is very rare (0-5%), and the vast majority of patients recover in few weeks. Erectile dysfunction can occur after focal therapy in 0-46%: the baseline function and the ablation template are the most important factors predicting post-operative erectile dysfunction. Focal therapy in the salvage setting after external beam radiotherapy has a significantly higher rate of complications. Up to one man in 10 will present a severe complication.
- Published
- 2021
9. A0649 - Effect of Metastasis Directed Therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series.
- Author
-
Mazzone, E., Gandaglia, G., Stabile, A., Cucchiara, V., Scuderi, S., Barletta, F., Nocera, L., Robesti, D., Pellegrino, F., Longoni, M., Pellegrino, A., Scilipoti, P., Cannoletta, D., Sorce, G., Samanes Gajate, A.M., Picchio, M., Ghezzo, S., Cozzarini, C., Chiti, A., and Montorsi, F.
- Subjects
- *
PROSTATE cancer , *METASTASIS , *THERAPEUTICS - Published
- 2024
- Full Text
- View/download PDF
10. A0287 - Optimizing detection and prediction of prostate cancer after positive MRI and negative biopsies.
- Author
-
Zattoni, F., Gandaglia, G., C N Van Den Bergh, R., Marra, G., Valerio, M., Olivier, J., Puche Sanzi, I., Rajwa, P., Maggi, M., Campi, R., Amparore, D., De Cillis, S., Guo, H., Veccia, A., Ditonno, F., Pereira, L.J., Barletta, F., Leni, R., Rivas, J.G., and Remmers, S.
- Subjects
- *
MAGNETIC resonance imaging , *BIOPSY , *FORECASTING , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
11. Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
- Author
-
Ploussard, G., Borgmann, H., Briganti, A., Visschere, P. De, Futterer, J.J., Gandaglia, G., Heidegger, I., Kretschmer, A., Mathieu, R., Ost, P., Sooriakumaran, P., Surcel, C., Tilki, D., Tsaur, I., Valerio, M., Bergh, R. van den, Group, E.-Y.P.C.W., Ploussard, G, Borgmann, H, Briganti, A, de Visschere, P, Futterer, Jj, Gandaglia, G, Heidegger, I, Kretschmer, A, Mathieu, R, Ost, P, Sooriakumaran, P, Surcel, C, Tilki, D, Tsaur, I, Valerio, M, and van den Bergh, R
- Subjects
Image-Guided Biopsy ,Male ,Nephrology ,Entire prostate ,medicine.medical_specialty ,Biopsy ,Urology ,030232 urology & nephrology ,Magnetic Resonance Imaging, Interventional ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Sampling (medicine) ,medicine.diagnostic_test ,business.industry ,Prostate ,Prostatic Neoplasms ,Cancer ,Magnetic resonance imaging ,Diagnostic strategy ,medicine.disease ,Magnetic Resonance Imaging ,030220 oncology & carcinogenesis ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Radiology ,business - Abstract
Item does not contain fulltext PURPOSE: The diagnostic strategy implementing multiparametric magnet resonance tomography (mpMRI) and targeted biopsies (TB) improves the detection and characterization of significant prostate cancer (PCa). We aimed to assess the clinical usefulness of systematic biopsies (SB) in the setting of patients having a pre-biopsy positive MRI. METHODS: A review of the literature was performed in March 2018. All studies investigating the performance of SB in addition to TB (all techniques) were assessed, both in the biopsy-naive and repeat biopsy setting. RESULTS: Evidence demonstrates that TB improves the detection of index-significant PCa compared with SB alone, in both initial and repeat biopsy settings. However, the combination of both TB and SB improved the overall (around 30%) and significant (around 10%) PCa detection rates as compared with TB alone. Significant differences between both biopsy approaches exist regarding cancer location favoring SB for the far lateral sampling, and TB for the anterior zone. Main current pitfalls of pure TB strategy are the learning curve and experience required for mpMRI reading and biopsy targeting, as well as the precision assessment in TB techniques. CONCLUSION: A pure TB strategy omitting SB leads to the risk of missing up to 15% of significant cancer, due to limitations of mpMRI performance/reading and of precision during lesion targeting. SB remain necessary, in addition to the TB, to obtain the most accurate assessment of the entire prostate gland in this sub-group of patients at risk of significant disease.
- Published
- 2019
12. Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?
- Author
-
Marra G, Ploussard G, Futterer J, Valerio M, De Visschere PJL, Tsaur I, Tilki D, Ost P, Gandaglia G, Van den Bergh RCN, Surcel C, Kretschmer A, Heidegger I, Borgmann H, Mathieu R, Marra, G, Ploussard, G, Futterer, J, Valerio, M, De Visschere, Pjl, Tsaur, I, Tilki, D, Ost, P, Gandaglia, G, Van den Bergh, Rcn, Surcel, C, Kretschmer, A, Heidegger, I, Borgmann, H, and Mathieu, R
- Subjects
Nephrology ,Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Cognitive ,MRI ,Prostate biopsy ,Targeted biopsy ,Transperineal ,Transrectal ,Biopsy ,Humans ,Image Processing, Computer-Assisted ,Magnetic Resonance Imaging, Interventional ,Perineum ,Prostate ,Prostatic Neoplasms ,Rectum ,Software ,Urology ,Image Processing ,030232 urology & nephrology ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Computer-Assisted ,Internal medicine ,medicine ,Medical physics ,medicine.diagnostic_test ,Interventional ,business.industry ,Cancer ,Cognition ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,business - Abstract
Item does not contain fulltext PURPOSE: To review the evidence addressing current controversies around prostate biopsy. Specific questions explored were (1) mpMRI targeted (TgBx) alone versus combined with systematic (SBx) biopsy; (2) cognitive versus software-based targeted biopsy; (3) transrectal or transperineal route (TP). METHODS: We performed a literature search of peer-reviewed English language articles using PubMed and the words "prostate" AND "biopsy". Web search was implemented by manual search. RESULTS: Prostate mpMRI is revolutionizing prostate cancer (PCa) diagnosis, and TgBx improves the detection of clinically significant (cs) PCa compared to SBx alone. The utility of combining SBx-TgBx is variable, but in non-expert centres the two should be combined to overcome learning curve-limitations. Whether SBx should be maintained in expert centres depends on what rate of missed cancer the urological community and patients are prone to accept; this has implications for insignificant cancer diagnosis as well. TgBx may be more precise using a software-based-approach despite cognitive TgBx proved non-inferior in some studies, and may be used for large accessible lesions. TP-biopsies are feasible in an in-office setting. Avoidance of the rectum and accessibility of virtually all prostate areas are attractive features. However, this has to be balanced with local setting and resources implications. Ongoing trials will shed light on unsolved issues. CONCLUSION: The prostate biopsy strategy should be tailored to local expertise, needs and resources availability. Targeted biopsy enhance the ratio between cs and insignificant cancer diagnosis, although some csPCa might be missed. Software-based TgBx are likely to be more precise, especially for new users, although the additional cost might be not justified in all cases. TPBx have ideal attributes for performing TgBx and avoiding infection, although this has resources implications.
- Published
- 2019
13. Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer.
- Author
-
Surcel, C., Mirvald, C., Tsaur, I., Borgmann, H., Heidegger, Isabel, Labanaris, A. P., Sinescu, I., Tilki, Derya, Ploussard, G., Briganti, A., Montorsi, F., Mathieu, R., Valerio, M., Jinga, V., Badescu, D., Radavoi, D., van den Bergh, R. C. N., Gandaglia, G., Kretschmer, A., and as part of the EAU-YAU PCa Working Party
- Subjects
PELVIC exenteration ,OVERALL survival ,SURVIVAL rate ,PROSTATE cancer ,OPERATIVE surgery ,COMPUTED tomography ,ILEAL conduit surgery - Abstract
Objective: To access the feasibility of palliative cystoprostatectomy/pelvic exenteration in patients with bladder/rectal invasion due to prostate cancer (PC). Patients and methods: Twenty-five men with cT4 PC were retrospectively identified in the institutional databases of six tertiary referral centers in the last decade. Local invasion was documented by CT or MRI scans and was confirmed by urethrocystoscopy. Oncological therapies, local symptoms, previous local treatments, time from diagnosis to intervention and type of surgical procedure were recorded. Patients were divided into groups: ADT group (12 pts) and 13 pts without any history of previous local/systemic treatments for PCa (nonADT groups). Perioperative complications were classified using the Clavien–Dindo system. Overall survival (OS) was defined as the time from surgery to death from any cause. A Cox regression analysis, stratified for ISUP score and previous hormonal treatment (ADT) was also performed for survival analysis. Results: Ileal conduit was the main urinary diversion in both cohorts. For the entire cohort, complication rate was 44%. No significant differences regarding perioperative complications and complication severity between both subgroups were observed (p = 0.2). Median follow-up was 15 months (range 3–41) for the entire cohort with a median survival of 15 months (95% CI 10.1–19.9). In Cox regression analysis stratified for ISUP score, no statistically significant differences in OS in patients with and without previous ADT before cystectomy or exenteration were observed (HR 3.26, 95% CI 0.62–17.23, p = 0.164). Conclusion: Palliative cystoprostatectomy and pelvic exenteration represent viable treatment options associated with acceptable morbidity and good short-term survival outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey
- Author
-
Marra, G, Ploussard, G, Ost, P, De Visschere, PJL, Briganti, A, Gandaglia, G, Tilki, D, Surcel, CI, Tsaur, I, Van Den Bergh, RCN, Kretschmer, A, Borgmann, H, Gontero, P, Ahmed, HU, Valerio, M, EAU-YAU Prostate Cancer Working Party, Marra, G, Ploussard, G, Ost, P, De Visschere, Pjl, Briganti, A, Gandaglia, G, Tilki, D, Surcel, Ci, Tsaur, I, Van den Bergh, Rcn, Kretschmer, A, Borgmann, H, Gontero, P, Ahmed, Hu, Valerio, M, and Wellcome Trust
- Subjects
Adult ,Male ,medicine.medical_specialty ,Multivariate analysis ,Urology ,030232 urology & nephrology ,Clinical practice ,European Association of Urology ,Focal therapy ,Prostate cancer ,Survey ,Young Academic Urologists ,03 medical and health sciences ,0302 clinical medicine ,Surveys and Questionnaires ,medicine ,Humans ,In patient ,business.industry ,Prostatic Neoplasms ,Negative opinion ,Middle Aged ,Urology & Nephrology ,Prognosis ,medicine.disease ,Checklist ,Europe ,Clinical Practice ,Cross-Sectional Studies ,Oncology ,030220 oncology & carcinogenesis ,Family medicine ,EAU-YAU Prostate Cancer Working Party ,business ,1112 Oncology And Carcinogenesis ,Follow-Up Studies - Abstract
Introduction: The urological community's opinion over focal therapy (FT) for prostate cancer (PCa) has never been assessed. Our aim was to investigate the current opinion on FT in the European urological community. Methods: A 25 -item questionnaire was devised according to the Cherries checklist and distributed through SurveyMonkey using a web link from November 2016 to October 2017. After a pilot validation (n=40 urologists), the survey was sent through EAU and 9 other national European urological societies mailing list. Twitter was also used. Results: We received 484 replies from 51 countries. Almost half (44.8%, n=217) stated FT would represent a step forward, and 52.0% (n=252) would suggest FT to a patient. Almost three-quarters (70.8%, n=343) agreed FT will become a standard option after improvements in patient selection (n=66) or when its effectiveness will be proven (n=78), or both (n=199). Most frequently used definition of FT was treatment of all significant (life -threatening) cancer foci whilst leaving untreated the rest of the gland (39.3%, n=190). FT use was considered as an alternative to whole -gland treatments by 29.7% (n=144), and to AS by 25.0% (n=121). On multivariate analysis, FT availability and publications were associated with a positive opinion on FT. Conversely, attending International congresses, treating high PCa volumes and high percentages of high -risk PCa was associated with a negative opinion. Conclusions: FT is considered as an attractive option for PCa treatment by the European urological community sampled by our survey. FT availability positively influences these thoughts. The present survey suggests whilst some early adopters already embraced FT, the relative majority of the urological community is prone to embrace FT in the near future, once current areas of debate are solved. (C) 2018 Elsevier Inc. All rights reserved.
- Published
- 2018
15. Imaging modalities in synchronous oligometastatic prostate cancer
- Author
-
Futterer, J.J., Surcel, C., Bergh, R. van den, Borgmann, H., Briganti, A., Gandaglia, G., Kretschmer, A., Ost, P., Sooriakumaran, P., Tilki, D., Valerio, M., Ploussard, G., Visschere, P.J. De, Tsaur, I., Party, E.-Y.P.C.W., EAU-YAU Prostate Cancer Working Party, Futterer, Jurgen J, Surcel, Cristian, van den Bergh, Roderick, Borgmann, Hendrik, Briganti, Alberto, Gandaglia, Giorgio, Kretschmer, Alexander, Ost, Piet, Sooriakumaran, Prasanna, Tilki, Derya, Valerio, Massimo, Ploussard, Guillaume, De Visschere, Pieter J L, and Tsaur, Igor
- Subjects
Nephrology ,Oncology ,Male ,medicine.medical_specialty ,PELVIC LYMPHADENECTOMY ,PET/CT ,Urology ,PET-CT ,030232 urology & nephrology ,Disease ,TERM ANDROGEN SUPPRESSION ,Multimodal Imaging ,Imaging modalities ,Imaging ,03 medical and health sciences ,Prostate cancer ,Oligometastatic ,0302 clinical medicine ,Internal medicine ,LOCAL TREATMENT ,Positron Emission Tomography Computed Tomography ,medicine ,Medicine and Health Sciences ,PSMA ,Humans ,Disseminated disease ,COMPUTED-TOMOGRAPHY ,Neoplasm Metastasis ,business.industry ,EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY ,RADICAL PROSTATECTOMY ,Cancer ,Prostatic Neoplasms ,medicine.disease ,Topic Paper ,Magnetic Resonance Imaging ,BONE-SCINTIGRAPHY ,Functional imaging ,METASTASES ,Neoplasm Metastasis/diagnostic imaging ,Positron-Emission Tomography ,Prostatic Neoplasms/diagnostic imaging ,Prostatic Neoplasms/pathology ,MRI ,030220 oncology & carcinogenesis ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,business ,RADIOTHERAPY - Abstract
Contains fulltext : 215808.pdf (Publisher’s version ) (Open Access) PURPOSE: Along with a number of other malignancies, the term "oligometastatic" prostate cancer has recently emerged. It represents an attempt to define a subtype of cancer with a limited metastatic load that might perform more favorably than a distinctly disseminated disease, or even one that may be managed in a potentially curative way. Since there is currently a knowledge gap of what imaging modalities should be utilized to classify patients as having this type of tumor, we aimed to shed light on the role of conventional and marker-based imaging in the setting of synchronous oligometastatic prostate cancer as well as summarize the available evidence for its clinical application. METHODS: A literature search on December 15th 2017 was conducted using the Pubmed database. RESULTS: Functional imaging techniques like (68)Ga PSMA. (68)Ga PSMA PET-CT has currently been shown the best detection rates for the assessment of nodal, bone and visceral metastases, especially for smaller lesions at low PSA levels. CONCLUSIONS: Functional imaging helps detect low-burden disease metastatic patients. However, these imaging modalities are not available in every center and thus clinicians may be prone to prescribe systemic treatment rather than referring patients for cytoreductive treatments. We hope that the ongoing prospective trials will help guide clinicians in making a more personalized management of synchronous metastatic patients.
- Published
- 2018
16. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer
- Author
-
Joniau, S, Spahn, M, Briganti, A, Gandaglia, G, Tombal, B, Tosco, L, Marchioro, G, Hsu, Cy, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, F, van Poppel, H, Gontero, Paolo, European Multicenter Prostate Cancer Clinical, Translational Research Group, Joniau, S, Spahn, M, Briganti, A, Gandaglia, G, Tombal, B, Tosco, L, Marchioro, G, Hsu, Cy, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, Francesco, van Poppel, H, and Gontero, P.
- Subjects
Oncology ,Male ,Biopsy ,Physics::Medical Physics ,Predictive Value of Test ,urologic and male genital diseases ,Prostate cancer ,Locally advanced prostate cancer ,Decision Support Technique ,Retrospective Studie ,Risk Factors ,Pretreatment table ,610 Medicine & health ,Pathologic stage ,Lymph Node ,Kallikrein ,Radical prostatectomy ,Europe ,Treatment Outcome ,Lymphatic Metastasis ,Kallikreins ,Human ,medicine.medical_specialty ,Logistic Model ,Quantitative Biology::Tissues and Organs ,Urology ,Locally advanced ,Reproducibility of Result ,Decision Support Techniques ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Neoplasm Staging ,Retrospective Studies ,Prostatectomy ,business.industry ,Risk Factor ,Patient Selection ,Prostatic Neoplasms ,Reproducibility of Results ,Lymphatic Metastasi ,Prostate-Specific Antigen ,medicine.disease ,Logistic Models ,Computer Science::Computer Vision and Pattern Recognition ,Prostatic Neoplasm ,Lymph Node Excision ,Lymph Nodes ,Neoplasm Grading ,business - Abstract
Background Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa. Objective To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice. Design, setting, and participants This was a multicenter retrospective cohort study including 759 consecutive patients with cT3a PCa treated with RP between 1987 and 2010. Intervention Retropubic RP and pelvic lymphadenectomy. Outcome measurements and statistical analysis Patients were divided into pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (GS) subgroups. These parameters were used to construct tables predicting pathologic outcome and the presence of positive lymph nodes (LNs) after RP for cT3a PCa using ordinal logistic regression. Results and limitations In the model predicting pathologic outcome, the main effects of biopsy GS and pretreatment PSA were significant. A higher GS and/or higher PSA level was associated with a more unfavorable pathologic outcome. The validation procedure, using a repeated split-sample method, showed good predictive ability. Regression analysis also showed an increasing probability of positive LNs with increasing PSA levels and/or higher GS. Limitations of the study are the retrospective design and the long study period. Conclusions These novel tables predict pathologic stage after RP for patients with cT3a PCa based on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa. Patient summary Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.
- Published
- 2015
17. Impact of time from diagnosis to treatment on erectile function outcomes after radical prostatectomy.
- Author
-
Schifano, N., Capogrosso, P., Pozzi, E., Ventimiglia, E., Cazzaniga, W., Matloob, R., Gandaglia, G., Dehò, F., Briganti, A., Montorsi, F., and Salonia, A.
- Subjects
SURGICAL diagnosis ,TREATMENT effectiveness ,DIAGNOSIS ,REGRESSION analysis ,PROSTATE cancer ,PROSTATECTOMY - Abstract
Background: Concerns exist about the effect of delaying treatment for prostate cancer (PCa) regarding both oncological and functional outcomes after radical prostatectomy (RP). Objective: To assess the impact of time from diagnosis to RP on post‐operative erectile function (EF) outcomes. Materials and methods: We analyzed data for 827 patients treated with RP at a single center from 2002 to 2017. The International Index of Erectile Function‐EF (IIEF‐EF) was compiled by every patient (EF recovery equal to IIEF‐EF ≥ 22). Time from diagnosis to treatment was defined as the interval between biopsy and RP. Cox regression analysis was used to test the impact of time to surgery on the probability of EF recovery. Kaplan–Meier analysis compared the cumulative incidence of EF recovery according to time from diagnosis to surgery. The impact of time to RP on EF was tested also in a sub‐cohort of patients eligible for active surveillance (AS). Results: Overall, low‐, intermediate‐, and high‐risk PCa was found in 306 (37%), 422 (51%), and 99 (12%) patients. Of them, 148 (17.9%) would have been eligible for AS. A total of 152 (18%) and 22 (2.7%) patients were treated after 6 and 12 months from diagnosis. The overall probability of EF recovery was 32% (95% CI: 29–36) at 24 months. Cox regression analysis showed that time from biopsy to surgery was not associated with a different chance of EF recovery (HR: 1.01; 95% CI: 0.97–1.05; p = 0.7). At Kaplan–Meier analysis, the cumulative incidence of EF recovery did not differ between patients treated within 6 months, from 6 to 12 months and after 12 months from diagnosis. Similar findings were obtained for patients eligible for AS. Discussion: Patients may be reassured regarding their chance of post‐operative EF recovery in the case of a delayed surgical treatment. Conclusions: Delaying surgery after PCa diagnosis does not affect post‐operative EF recovery outcomes regardless of oncological risk. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis
- Author
-
Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, MONTORSI , FRANCESCO, Briganti A, Trinh QD, Karakiewicz PI, Sun M., Gandaglia, G, Abdollah, F, Schiffmann, J, Trudeau, V, Shariat, Sf, Kim, Sp, Perrotte, P, Montorsi, Francesco, Briganti, A, Trinh, Qd, Karakiewicz, Pi, and Sun, M.
- Subjects
Aged, 80 and over ,Male ,United State ,Databases, Factual ,Urology ,Kidney Neoplasm ,Lymphatic Metastasi ,Bone Neoplasm ,Middle Aged ,prostate cancer ,sites of metastase ,Thoracic Neoplasm ,Adrenal Gland Neoplasm ,Brain Neoplasm ,Lung Neoplasm ,Oncology ,Liver Neoplasm ,Retrospective Studie ,Prostatic Neoplasm ,Prevalence ,metastatic disease ,bone metastase ,Aged ,Human - Abstract
BACKGROUNDThere is few data on what constitutes the distribution of metastatic sites in prostate cancer (PCa). The aim of our study was to systematically describe the most common sites of metastases in a contemporary cohort of PCa patients. METHODSPatients with metastatic PCa were abstracted from the Nationwide Inpatient Sample (1998-2010). Most common metastatic sites within the entire population were described. Stratification was performed according to the presence of single or multiple (2 sites) metastases. Additionally, we evaluated the distribution of metastatic sites amongst patients with and without bone metastases. RESULTSOverall, 74,826 patients with metastatic PCa were identified. The most common metastatic sites were bone (84%), distant lymph nodes (10.6%), liver (10.2%), and thorax (9.1%). Overall, 18.4% of patients had multiple metastatic sites involved. When stratifying patients according to the site of metastases, only 19.4% of men with bone metastases had multiple sites involved. Conversely, among patients with lymph nodes, liver, thorax, brain, digestive system, retroperitoneum, and kidney and adrenal gland metastases the proportion of men with multiple sites involved was 43.4%, 76.0%, 76.7%, 73.0%, 52.2%, 60.9%, and 76.4%, respectively. When focusing exclusively on patients with bone metastases, the most common sites of secondary metastases were liver (39.1%), thorax (35.2%), distant lymph nodes (24.6%), and brain (12.4%). CONCLUSIONSAlthough the majority of patients with metastatic PCa experience bone location, the proportion of patients with atypical metastases is not negligible. These findings might be helpful when planning diagnostic imaging procedures in patients with advanced PCa. Prostate 74:210-216, 2014. (c) 2013 Wiley Periodicals, Inc.
- Published
- 2014
19. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis
- Author
-
Gandaglia, G, Sun, M, Trinh, Qd, Becker, A, Schiffmann, J, Hu, Jc, BRIGANTI, ALBERTO, MONTORSI, FRANCESCO, Perrotte, P, Karakiewicz, Pi, Abdollah, F., Gandaglia, G, Sun, M, Trinh, Qd, Becker, A, Schiffmann, J, Hu, Jc, Briganti, Alberto, Montorsi, Francesco, Perrotte, P, Karakiewicz, Pi, and Abdollah, F.
- Subjects
Male ,United State ,Prostatectomy ,observation ,Radiotherapy ,Urology ,prostate cancer ,Risk Assessment ,radical prostatectomy ,Survival Rate ,Prostatic Neoplasm ,survival benefit ,Neoplasm Grading ,Propensity Score ,Watchful Waiting ,locally-advanced ,Aged ,Human ,Neoplasm Staging ,SEER Program ,Numbers Needed To Treat - Abstract
Objective To describe the survival benefit associated with radical prostatectomy (RP), as compared with initial observation, in patients with locally advanced prostate cancer (PCa).Patients and Methods Overall, 1382 patients with locally advanced PCa treated with RP or initial observation between 1995 and 2009 were identified from the Surveillance, Epidemiology and End Results Medicare insurance programme-linked database. Patients were matched using propensity-score methodology, then 10-year cancer-specific mortality (CSM) rates were estimated and the number needed to treat (NNT) was calculated. Competing-risks regression analyses tested the relationship between treatment type and CSM.Results Overall, the 10-year CSM rates were 11.8 and 19.3% for patients treated with RP and initial observation, respectively (P < 0.001). The corresponding 10-year NNT was 13. The 10-year CSM rates for the same treatment groups were 8.9 vs 13.9%, respectively, for Gleason score â¤7, 16.8 vs 27.8%, respectively, for Gleason score 8-10, 10.1 vs 15.8%, respectively, for clinical stage T3a, and 17.0 vs 29.3%, respectively, for T3b/T4, respectively (all P ⤠0.04). The corresponding NNTs were 20, 9, 17 and 8, respectively. In multivariable analyses, RP was an independent predictor of more favourable CSM rates in all categories (all P ⤠0.04). In separate sensitivity analyses, no differences were recorded when patients treated with radiotherapy were compared with those receiving RP (P = 0.4). Conversely, patients undergoing initial observation had a higher risk of CSM compared with those treated with radiotherapy (P = 0.03).Conclusions RP leads to a significant survival advantage compared with observation in patients with locally advanced disease. The highest benefit was observed in patients with T3b/T4 and Gleason score 8-10 disease.
- Published
- 2014
20. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study
- Author
-
Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, MONTORSI , FRANCESCO, Karakiewicz PI, Gandaglia, G, Sun, M, Popa, I, Schiffmann, J, Abdollah, F, Trinh, Qd, Saad, F, Graefen, M, Briganti, A, Montorsi, Francesco, and Karakiewicz, Pi
- Subjects
Male ,United State ,Risk Factor ,Urology ,Myocardial Infarction ,Coronary Disease ,prostate cancer ,cardiovascular event ,Gonadotropin-Releasing Hormone ,Death, Sudden, Cardiac ,Prostatic Neoplasm ,androgen-deprivation therapy ,Androgen Antagonist ,Cohort Studie ,Propensity Score ,side-effect ,Orchiectomy ,Aged ,Human ,SEER Program - Abstract
Objective To examine and quantify the contemporary association between androgen-deprivation therapy (ADT) and three separate endpoints: coronary artery disease (CAD), acute myocardial infarction (AMI), and sudden cardiac death (SCD), in a large USA contemporary cohort of patients with prostate cancer.Patients and Methods In all, 140474 patients diagnosed with non-metastatic prostate cancer between 1995 and 2009 within the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database were abstracted. Patients treated with ADT and those not receiving ADT were matched using propensity score methodology. The 10-year CAD, AMI, and SCD rates were estimated. Competing-risks regression analyses tested the association between the type of ADT (GnRH agonists vs bilateral orchidectomy) and CAD, AMI, and SCD, after adjusting for the risk of dying during follow-up.Results Overall, the 10-year rates of CAD, AMI, and SCD were 25.9%, 15.6%, and 15.8%, respectively. After stratification according to ADT status (ADT-naïve vs GnRH agonists vs bilateral orchidectomy), the CAD rates were 25.1% vs 26.9% vs 23.2%, the AMI rates were 14.8% vs 16.6% vs 14.8%, and the SCD rates were 14.2% vs 17.7% vs 16.4%, respectively. In competing-risks multivariable regression analyses, the administration of GnRH agonists (all P < 0.001), but not bilateral orchidectomy (all P ⥠0.7), was associated with higher risk of CAD, AMI, and SCD.Conclusions The administration of GnRH agonists, but not orchidectomy, is still associated with a significantly increased risk of CAD, AMI, and, especially, SCD in patients with non-metastatic prostate cancer. Alternative forms of ADT should be considered in patients at higher risk of CV events.
- Published
- 2014
21. A1233 - Has the introduction of multiparametric magnetic resonance imaging of the prostate and targeted biopsies led to a risk of overgrading of high risk prostate cancer? Results from a contemporary, large multi-institutional series.
- Author
-
Sorce, G., Gandaglia, G., Stabile, A., Cucchiara, V., Mazzone, E., Fossati, N., Moschini, M., Mattei, A., Afferi, L., Serni, S., Minervini, A., Rahota, R-G., Ploussard, G., Valerio, M., Beavaul, J.B., Marquis, A., Rakauskas, A., Gontero, P., Guo, H., and Zhuang, J.
- Subjects
- *
PROSTATE cancer , *MAGNETIC resonance imaging , *DISEASE risk factors , *PROSTATE biopsy - Published
- 2023
- Full Text
- View/download PDF
22. A1226 - Improving prediction of local stage by PSMA-PET: Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer.
- Author
-
Scuderi, S.L.A., Gandaglia, G., Barletta, F., Bianchi, L., Zattoni, F., Dal Moro, F., Reitano, G., Rajwa, P., Hübner, N., Shariat, S., Kesch, C., Darr, C., Fendler, W., Gomez-Rivas, J., Moreno-Sierra, J., Marra, G., Guo, H., Zhuang, J., Amparore, D., and Checcucci, E.
- Subjects
- *
SEMINAL vesicles , *DIAGNOSTIC imaging , *PROSTATE cancer , *FORECASTING - Published
- 2023
- Full Text
- View/download PDF
23. A1120 - Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy.
- Author
-
Mazzone, E., Gandaglia, G., Stabile, A., Robesti, D., Necchi, A., Raggi, D., Marandino, L., Cirulli, G., Scuderi, S., Barletta, F., Pellegrino, A.A., De Angelis, M., Cucchiara, V., Rosiello, G., Sorce, G., Nocera, L., Pellegrino, F., Longoni, M., Scilipoti, P., and Quarta, L.
- Subjects
- *
RADICAL prostatectomy , *PROSTATE cancer - Published
- 2023
- Full Text
- View/download PDF
24. A0998 - A systematic review to evaluate Patient-Reported Outcomes Measures (PROMs) for metastatic prostate cancer according to the COSMIN methodology – A PIONEER wp2 project.
- Author
-
Ratti, M.M., Gandaglia, G., Armando, S., Mazzone, E., Scuderi, S., Barletta, F., Mottet, N., Williamson, P.R., Moss, C., Beyer, K., Muhammad Imran, O., Maclennan, S., Zong, J., Cornford, P., Maclennan, S.J., Aiyegbusi, O.L., Van Hemelrijck, M., Alleva, E., Derevianko, A., and Sisca, E.S.
- Subjects
- *
PATIENT reported outcome measures , *METASTASIS , *PROSTATE cancer - Published
- 2023
- Full Text
- View/download PDF
25. A0647 - Is there a preferential lymph node metastasis pathway in prostate cancer according to the site of the index lesion at multiparametric MRI? A topographic mapping study.
- Author
-
Pellegrino, F., Gandaglia, G., Stabile, A., Cucchiara, V., Mazzone, E., Scuderi, S., Barletta, F., Robesti, D., Pellegrino, A., Quarta, L., Zaurito, P., Tenace, N., Brembilla, G., Lucianò, R., De Cobelli, F., Montorsi, F., and Briganti, A.
- Subjects
- *
LYMPHATIC metastasis , *TOPOGRAPHIC maps , *MAGNETIC resonance imaging , *PROSTATE cancer - Published
- 2023
- Full Text
- View/download PDF
26. A0264 - Exploring the effect of metastasis directed therapy on progression patterns of patients with positive 68Ga-PSMA PET/CT and biochemical recurrence from prostate cancer.
- Author
-
Pellegrino, A., Gandaglia, G., Stabile, A., Cucchiara, V., Mazzone, E., Necchi, A., Raggi, D., Marandino, L., Rosiello, G., Sorce, G., Pellegrino, F., Scuderi, S., Barletta, F., Robesti, D., De Angelis, M., Longoni, M., Scilipoti, P., Montorsi, F., and Briganti, A.
- Subjects
- *
PROSTATE cancer , *METASTASIS , *PATIENTS - Published
- 2023
- Full Text
- View/download PDF
27. A0090 - mpMRI of the prostate in patients carrying a high clinical risk of prostate cancer diagnosis: Is this imaging test necessary for diagnostic purposes in this subset of patients?
- Author
-
Stabile, A., Gandaglia, G., Pellegrino, F., Afferi, L., Zhuang, J., Guo, H., Gontero, P., Minervini, A., Ploussard, G., Mazzone, E., Valerio, M., Cucchiara, V., Fossati, N., Moschini, M., Mattei, A., Serni, S., Rahota, R., Beauval, J.B., Marquis, A., and Rakauskas, A.
- Subjects
- *
PROSTATE cancer , *CANCER diagnosis , *DISEASE risk factors , *PROSTATE , *DIAGNOSIS methods - Published
- 2023
- Full Text
- View/download PDF
28. A0091 - Integrating index lesion volume to better classify men with indolent prostate cancer among patients with intermediate risk disease. Results from a large, multi-institutional series.
- Author
-
Stabile, A., Gandaglia, G., Pellegrino, F., Mazzone, E., Cucchiara, V., Fossati, N., Moschini, M., Mattei, A., Afferi, L., Serni, S., Minervini, A., Rahota, R-G., Ploussard, G., Valerio, M., Beauval, J.B., Marquis, A., Rakauskas, A., Gontero, P., Guo, H., and Zhuang, J.
- Subjects
- *
PROSTATE cancer patients , *PROSTATE cancer - Published
- 2023
- Full Text
- View/download PDF
29. Stratification of high-risk prostate cancer into prognostic categories: A european multi-institutional study
- Author
-
Joniau, S, Briganti, A, Gontero, Paolo, Gandaglia, G, Tosco, L, Fieuws, S, Tombal, B, Marchioro, G, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, F, Van Poppel, H, Spahn, M, European Multicenter Prostate Cancer Clinical, Translational Research Group, Joniau, Steven, Briganti, Alberto, Gontero, Paolo, Gandaglia, Giorgio, Tosco, Lorenzo, Fieuws, Steffen, Tombal, Bertrand, Marchioro, Giansilvio, Walz, Jochen, Kneitz, Burkhard, Bader, Pia, Frohneberg, Detlef, Tizzani, Alessandro, Graefen, Marku, van Cangh, Paul, Karnes R., Jeffrey, Montorsi, Francesco, Van Poppel, Hein, and Spahn, Martin
- Subjects
Oncology ,High-risk prostate cancer ,Male ,medicine.medical_specialty ,Urology ,Predictive Value of Test ,Disease ,Risk Assessment ,Stratification (mathematics) ,Disease-Free Survival ,Prostate cancer ,Locally advanced prostate cancer ,Risk groups ,Predictive Value of Tests ,Risk Factors ,Retrospective Studie ,Internal medicine ,medicine ,Humans ,Risk stratification ,Proportional Hazards Models ,Retrospective Studies ,Aged ,Neoplasm Staging ,business.industry ,Risk Factor ,Risk group ,Prostatic Neoplasms ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Europe ,Survival Rate ,Area Under Curve ,Prostatic Neoplasm ,Proportional Hazards Model ,Neoplasm Grading ,business ,Human - Abstract
Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage ( 20 ng/ml). The first "extended" model includes all seven possible combinations; the second "simplified" model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA > 20 ng/ml and stage cT3-4); and a poor prognosis subgroup (GS 8-10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R: 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively (p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.
- Published
- 2015
30. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control
- Author
-
Hu, JC, Gandaglia, G, Karakiewicz, PI, Nguyen, PL, Trinh, Q-D, Shih, Y-CT, Abdollah, F, Chamie, K, Wright, JL, Ganz, PA, and Sun, M
- Subjects
Male ,Urologic Diseases ,Aging ,Comparative Effectiveness Research ,Clinical Sciences ,Risk Assessment ,Cohort Studies ,Robotic Surgical Procedures ,Clinical Research ,Confidence Intervals ,Odds Ratio ,Humans ,Neoplasm Invasiveness ,Neoplasm Staging ,Retrospective Studies ,Aged ,Cancer ,Prostatectomy ,Robotic-assisted surgery ,Prostate Cancer ,Prostatic Neoplasms ,Evaluation of treatments and therapeutic interventions ,Prostate-Specific Antigen ,Middle Aged ,Urology & Nephrology ,Radical prostatectomy ,Neoplasm Recurrence ,Treatment Outcome ,Local ,Linear Models ,Patient Safety ,Positive margins ,6.4 Surgery ,Follow-Up Studies ,Cancer control - Abstract
Background: Robot-assisted radical prostatectomy (RARP) remains controversial, and no improvement in cancer control outcomes has been demonstrated over open radical prostatectomy (ORP). Objective: To examine population-based, comparative effectiveness of RARP versus ORP pertaining surgical margin status and use of additional cancer therapy. Design, setting, and participants: This was a retrospective observational study of 5556 RARP and 7878 ORP cases from 2004 to 2009 from Surveillance Epidemiology and End Results-Medicare linked data. Intervention: RARP versus ORP. Outcome measurements and statistical analysis: Propensity-based analyses were performed to minimize treatment selection biases. Generalized linear regression models were computed for comparison of RP surgical margin status and use of additional cancer therapy (radiation therapy [RT] or androgen deprivation therapy [ADT]) by surgical approach. Results and limitations: In the propensity-adjusted analysis, RARP was associated with fewer positive surgical margins (13.6% vs 18.3%; odds ratio [OR]: 0.70; 95% confidence interval [CI], 0.66-0.75), largely because of fewer RARP positive margins for intermediate-risk (15.0% vs 21.0%; OR: 0.66; 95% CI, 0.59-0.75) and high-risk (15.1% vs 20.6%; OR: 0.70; 95% CI, 0.63-0.77) disease. In addition, RARP was associated with less use of additional cancer therapy within 6 mo (4.5% vs 6.2%; OR: 0.75; 95% CI, 0.69-0.81), 12 mo (OR: 0.73; 95% CI, 0.62-0.86), and 24 mo (OR: 0.67; 95% CI, 0.57-0.78) of surgery. Limitations include the retrospective nature of the study and the absence of prostate-specific antigen levels to determine biochemical recurrence. Conclusions: RARP is associated with improved surgical margin status relative to ORP for intermediate- and high-risk disease and less use of postprostatectomy ADT and RT. This has important implications for quality of life, health care delivery, and costs. Patient summary: Robot-assisted radical prostatectomy (RP) versus open RP is associated with fewer positive margins and better early cancer control because of less use of additional androgen deprivation and radiation therapy within 2 yr of surgery. © 2014 European Association of Urology.
- Published
- 2014
31. Long-term penile morphometric alterations in patients treated with robot-assisted versus open radical prostatectomy.
- Author
-
Capogrosso, P., Ventimiglia, E., Cazzaniga, W., Stabile, A., Pederzoli, F., Boeri, L., Gandaglia, G., Dehò, F., Briganti, A., Montorsi, F., and Salonia, A.
- Subjects
PROSTATECTOMY ,SURGICAL robots ,MALE infertility ,PENIS abnormalities ,LOGISTIC regression analysis ,BODY mass index - Abstract
Neglected side effects after radical prostatectomy have been previously reported. In this context, the prevalence of penile morphometric alterations has never been assessed in robot-assisted radical prostatectomy series. We aimed to assess prevalence of and predictors of penile morphometric alterations (i.e. penile shortening or penile morphometric deformation) at long-term follow-up in patients submitted to either robot-assisted (robot-assisted radical prostatectomy) or open radical prostatectomy. Sexually active patients after either robot-assisted radical prostatectomy or open radical prostatectomy prospectively completed a 28-item questionnaire, with sensitive issues regarding sexual function, namely orgasmic functioning, climacturia and changes in morphometric characteristics of the penis. Only patients with a post-operative follow-up ≥ 24 months were included. Patients submitted to either adjuvant or salvage therapies or those who refused to comprehensively complete the questionnaire were excluded from the analyses. A propensity-score matching analysis was implemented to control for baseline differences between groups. Logistic regression models tested potential predictors of penile morphometric alterations at long-term post-operative follow-up. Overall, 67 (50%) and 67 (50%) patients were included after open radical prostatectomy or robot-assisted radical prostatectomy, respectively. Self-rated post-operative penile shortening and penile morphometric deformation were reported by 75 (56%) and 29 (22.8%) patients, respectively. Rates of penile shortening and penile morphometric deformation were not different after open radical prostatectomy and robot-assisted radical prostatectomy [all p > 0.5]. At univariable analysis, self-reported penile morphometric alterations (either penile shortening or penile morphometric deformation) were significantly associated with baseline international index of erectile function-erectile function scores, body mass index, post-operative erectile function recovery, year of surgery and type of surgery (all p < 0.05). At multivariable analysis, robot-assisted radical prostatectomy was independently associated with a lower risk of post-operative penile morphometric alterations (OR: 0.38; 95% CI: 0.16-0.93). Self-perceived penile morphometric alterations were reported in one of two patients after radical prostatectomy at long-term follow-up, with open surgery associated with a potential higher risk of this self-perception. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. A0972 - Impact of Prostate Imaging Quality (PI-QUAL) score on the detection of clinically significant prostate cancer in men undergoing MRI-targeted biopsy.
- Author
-
Brembilla, G., Gandaglia, G., Stabile, A., Mazzone, E., Sorce, G., Pellegrino, F., Robesti, D., Pellegrino, A., Longoni, M., Scilipoti, P., Quarta, L., Zaurito, P., Di Gaeta, E., Lavalle, S., Cosenza, M., Montorsi, F., Briganti, A., Esposito, A., and De Cobelli, F.
- Subjects
- *
PROSTATE cancer patients , *ENDORECTAL ultrasonography , *PROSTATE cancer , *PROSTATE , *BIOPSY - Published
- 2023
- Full Text
- View/download PDF
33. A0648 - Defining the optimal target-to-background count rate to identify positive lymph nodes in patients undergoing robot-assisted 99mtc-PSMA-radioguided surgery for prostate cancer: A per-region analysis of a prospective, phase II study.
- Author
-
Mazzone, E., Gandaglia, G., Stabile, A., Cucchiara, V., Rosiello, G., Sorce, G., Pellegrino, F., Scuderi, S., Barletta, F., Robesti, D., Leni, R., De Angelis, M., Pellegrino, A., Longoni, M., Scilipoti, P., Brembilla, G., De Cobelli, F., Samanes Gajate, A.M., Picchio, M., and Gianolli, L.
- Subjects
- *
SURGICAL robots , *PROSTATE surgery , *LYMPH nodes , *ONCOLOGIC surgery , *PROSTATE cancer - Published
- 2023
- Full Text
- View/download PDF
34. A0833 - When Is Neoadjuvant Androgen Deprivation Therapy Beneficial for Highly Aggressive Prostate Cancer Before Radical Prostatectomy? Implications for Multi-modal Tailored Approaches and Trials Design.
- Author
-
Barletta, F.M., Gandaglia, G., Scuderi, S., De Angelis, M., Toneatto, L., Quarta, L., Robesti, D., Cannoletta, D., Cirulli, G.O., Stabile, A., Cucchiara, V., Nocera, L., Raggi, D., Marandino, L., Necchi, A., Mazzone, E., Zaffuto, E., Karakiewicz, P.I., Montorsi, F., and Briganti, A.
- Subjects
- *
ANDROGEN deprivation therapy , *RADICAL prostatectomy , *PROSTATE cancer - Published
- 2022
- Full Text
- View/download PDF
35. A0742 - Detection of clinically significant prostate cancer in mpMRI visible lesions: Size matters. Results from a large, two-institutional series.
- Author
-
Stabile, A., Gandaglia, G., Mazzone, E., Barletta, F., Robesti, D., Cirulli, G.O., Cannoletta, D., Pellegrino, F., Nocera, L., Sorce, G., De Angelis, M., Bravi, C., Cucchiara, V., Martini, A., Fossati, N., De Cobelli, F., Esposito, A., Brembilla, G., Seisen, T., and Roupret, M.
- Subjects
- *
PROSTATE cancer - Published
- 2022
- Full Text
- View/download PDF
36. A0736 - Does a positive multi-parametric MRI always warrant prostate biopsy? The importance of integrating clinical and imaging data based on a large, multi-institutional series.
- Author
-
Stabile, A., Gandaglia, G., Mazzone, E., Barletta, F., Scuderi, S., Robesti, D., Cirulli, G.O., Cannoletta, D., Pellegrino, F., Nocera, L., Sorce, G., De Angelis, M., Bravi, C.A., Martini, A., Seisen, T., Roupret, M., Karnes, J.R., Fossati, N., De Cobelli, F., and Esposito, A.
- Subjects
- *
PROSTATE biopsy , *DIAGNOSTIC imaging , *MAGNETIC resonance imaging , *PROSTATE cancer - Published
- 2022
- Full Text
- View/download PDF
37. A0618 - Definition and predictors of upgrading at final pathology in prostate cancer patients undergoing mri-targeted and systematic biopsies: Results from a large, multi-institutional series.
- Author
-
Gandaglia, G., Mazzone, E., Ploussard, G., Marra, G., Valerio, M., Campi, R., Mari, A., Minervini, A., Serni, S., Moschini, M., Marquis, A., Beauval, J.-B., Rakauskas, A., Sessa, F., Van Den Bergh, R.C.N., Rahota, R-G., Soeterik, T., Roumiguié, M., Afferi, L., and Zhuang, J.
- Subjects
- *
PROSTATE cancer patients , *PROSTATE cancer , *ENDORECTAL ultrasonography , *PATHOLOGY , *GLEASON grading system , *BIOPSY , *DEFINITIONS - Published
- 2022
- Full Text
- View/download PDF
38. The effect of age at diagnosis on prostate cancer mortality: A grade-for-grade and stage-for-stage analysis.
- Author
-
Gandaglia, G., Karakiewicz, P.I., Abdollah, F., Becker, A., Roghmann, F., Sammon, J.D., Kim, S.P., Perrotte, P., Briganti, A., Montorsi, F., Trinh, Q.-D., and Sun, M.
- Subjects
PROSTATE cancer treatment ,PROSTATE cancer ,DIAGNOSIS ,CANCER-related mortality ,PROSTATECTOMY ,EPIDEMIOLOGY of cancer ,MEDICAL databases - Abstract
Objective To evaluate the effect of advancing age on cancer-specific mortality (CSM) after radical prostatectomy (RP). Materials and methods Overall, 205,551 patients with PCa diagnosed between 1988 and 2009 within the Surveillance Epidemiology and End Results (SEER) database were included in the study. Patients were stratified according to age at diagnosis: ≤50, 51–60, 61–70, and ≥71 years. The 15-year cumulative incidence CSM rates were computed. Competing-risks regression models were performed to test the effect of age on CSM in the entire cohort, and for each grade (Gleason score 2–4, 5–7, and 8–10) and stage (pT2, pT3a, and pT3b) sub-cohorts. Results Advancing age was associated with higher 15-year CSM rates (2.3 vs. 3.4 vs. 4.6 vs. 6.3% for patients aged ≤50 vs. 51–60 vs. 61–70 vs. ≥71 years, respectively; P < 0.001). In multivariable analyses, age at diagnosis was a significant predictor of CSM. This relationship was also observed in sub-analyses focusing on patients with Gleason score 5–7, and/or pT2 disease (all P ≤ 0.05). Conversely, age failed to reach the independent predictor status in men with Gleason score 2–4, 8–10, pT3a, and/or pT3b disease. Conclusions Advancing age increases the risk of CSM. However, when considering patients affected by more aggressive disease, age was not significantly associated with higher risk of dying from PCa. In high-risk patients, tumor characteristics rather than age should be considered when making treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study.
- Author
-
Gandaglia, G., Karakiewicz, P. I., Briganti, A., Trinh, Q. D., Schiffmann, J., Tian, Z., Kim, S. P., Nguyen, P. L., Graefen, M., Montorsi, F., Sun, M., and Abdollah, F.
- Subjects
- *
RADIOTHERAPY , *PROSTATE cancer patients , *PROSTATE cancer risk factors , *MEDICAL care , *EPIDEMIOLOGY , *COMPARATIVE studies - Abstract
In patients with low/intermediate-risk PCa, IMRT was not associated with a PCa-specific survival improvement. Conversely, this approach leads to a significant survival advantage in patients with high-risk disease. The highest survival benefit was observed among younger and healthier patients.Background During the last years, there has been a rapid adoption of intensity-modulated radiation therapy (IMRT) in patients with prostate cancer (PCa), despite the lack of randomized trials evaluating its effectiveness. The aim of our study was to evaluate the survival benefit associated with IMRT in patients with PCa. Patients and methods Overall, 42 483 patients with PCa treated with IMRT or initial observation between 2001 and 2007 within the Surveillance, Epidemiology, and End Results (SEER)-Medicare were evaluated. Patients in both treatment arms were matched using propensity-score methodology. After propensity-score matching, 19 064 patients remained in our analyses. Eight-year cancer-specific mortality (CSM) rates were estimated, and the number needed to treat (NNT) was calculated. Competing risks regression analyses tested the relationship between treatment type and CSM. Results Overall, the 8-year CSM rates were 3.4% and 4.1% for patients treated with IMRT versus initial observation, respectively (P < 0.001). The corresponding 8-year NNT was 142. In patients with low/intermediate-risk disease, IMRT was not associated with lower CSM rates compared with observation (P = 0.7). In patients with high-risk disease, the 8-year CSM rates for IMRT versus observation were 5.8% versus 10.5%, respectively (P < 0.001). The corresponding NNT was 21. When high-risk patients were stratified according to age (<73 versus ≥73), and Charlson comorbidity index (≤1 versus >1) the 8-year CSM rates for IMRT versus observation were 4.3% versus 9.4% and 6.9% versus 11.9% and 5.3% versus 11.4% and 6.1% versus 10.1%, respectively (all Ps < 0.001). The corresponding NNTs were 19, 21, 16, and 25, respectively. In multivariate analyses, the protective effect of IMRT was more evident in high-risk patients with younger age and lower comorbidities. Conclusions IMRT leads to a survival advantage only in patients with high-risk disease. Conversely, patients with low/intermediate-risk disease did not benefit from IMRT at 8-year follow-up. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
40. A0658 - Impact of the time elapsed between prostate biopsy and surgery on the accuracy of the Briganti nomogram predicting lymph node invasion in men with clinically localized prostate cancer.
- Author
-
Gandaglia, G., Mazzone, E., Zaffuto, E., Sorce, G., Pellegrino, F., Nocera, L., Stabile, A., Capitanio, U., Larcher, A., Dehò, F., Salonia, A., Karakiewicz, P.I., Shariat, S., Montorsi, F., and Briganti, A.
- Subjects
- *
PROSTATE surgery , *PROSTATE biopsy , *LYMPH nodes , *PROSTATE cancer , *NOMOGRAPHY (Mathematics) , *PROSTATECTOMY - Published
- 2022
- Full Text
- View/download PDF
41. 466 - Development of novel criteria for active surveillance based on multiparametric MRI alone in men with Gleason 3+4 prostate cancer: Use of imaging to safely expand the eligibility for active surveillance.
- Author
-
Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J., Malavaud, B., Roumiguié, M., Dell'Oglio, P., Suardi, N., Moschini, M., Zamboni, S., Rakauskas, A., Mirone, V., De Cobelli, F., Porpiglia, F., Montorsi, F., and Briganti, A.
- Subjects
- *
PROSTATE cancer , *IMAGING of cancer , *MEDICAL radiology , *TECHNICAL specifications - Published
- 2019
- Full Text
- View/download PDF
42. 216 - Which patients with clinically node positive prostate cancer should be considered as candidates for radical prostatectomy as part of a multimodal treatment? The impact of nodal burden.
- Author
-
Gandaglia, G., Karnes, R.J., Devos, G., Battaglia, A., Muilwijk, T., Soligo, M., Evaraerts, W., Boeri, L., Scuderi, S., Stabile, A., Robesti, D., Dell'Oglio, P., Bandini, M., Fossati, N., Moschini, M., Joniau, S., Montorsi, F., and Briganti, A.
- Subjects
- *
PROSTATE cancer , *COMBINED modality therapy , *LYMPHADENECTOMY - Published
- 2019
- Full Text
- View/download PDF
43. 153 - Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for treatment selection.
- Author
-
Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J., Malavaud, B., Roumiguié, M., Robesti, D., Dell'Oglio, P., Dehò, F., Capitanio, U., Moschini, M., Zamboni, S., Rakauskas, A., De Cobelli, F., Porpiglia, F., and Montorsi, F.
- Subjects
- *
PROSTATE cancer , *PATIENT selection , *PROSTATE cancer patients , *BIOPSY - Published
- 2019
- Full Text
- View/download PDF
44. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review
- Author
-
Ratti, M.M., Gandaglia, G., Alleva, E., Leardini, L., Sisca, E.S., Derevianko, A., Furnari, F., Ferracini, S. Mazzoleni, Beyer, K., Moss, C., Pellegrino, F., Sorce, G., Barletta, F., Scuderi, S., Omar, M.I., MacLennan, S., Williamson, P.R., Zong, J., MacLennan, S.J., Mottet, N., Cornford, P., Aiyegbusi, O.L., Hemelrijck, M. Van, N'Dow, J., Briganti, A., and Huisman, H.J.
- Subjects
Male ,medicine.medical_specialty ,Psychometrics ,Urology ,MEDLINE ,Context (language use) ,Prostate cancer ,Percutaneous Coronary Intervention ,Cronbach's alpha ,Quality of life ,Content validity ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Patient Reported Outcome Measures ,business.industry ,Prostatic Neoplasms ,social sciences ,medicine.disease ,humanities ,Oncology ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Physical therapy ,Quality of Life ,Surgery ,Patient-reported outcome ,Sexual function ,business - Abstract
Contains fulltext : 288444.pdf (Publisher’s version ) (Open Access) CONTEXT: Prostate cancer (PCa) is the second most common cancer among men worldwide. Urinary, bowel, and sexual function, as well as hormonal symptoms and health-related quality of life (HRQoL), were prioritised by patients and professionals as part of a core outcome set for localised PCa regardless of treatment type. OBJECTIVE: To systematically review the measurement properties of patient-reported outcome measures (PROMs) used in localised PCa and recommend PROMs for use in routine practice and research settings. EVIDENCE ACQUISITION: The psychometric properties of PROMs measuring functional and HRQoL domains used in randomised controlled trials including patients with localised PCa were assessed according to the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) methodology. MEDLINE and Embase were searched to identify publications evaluating psychometric properties of the PROMs. The characteristics and methodological quality of the studies included were extracted, tabulated, and assessed according to the COSMIN criteria. EVIDENCE SYNTHESIS: Overall, 27 studies evaluating psychometric properties of the Expanded Prostate Cancer Index Composite (EPIC), University of California-Los Angeles Prostate Cancer Index (UCLA-PCI), European Organisation for Research and Treatment of Cancer (EORTC) quality of life core 30 (QLQ-C30) and prostate cancer 25 (QLQ-PR25) modules, International Index of Erectile Function (IIEF), and the 36-item (SF-36) and 12-item Short-Form health survey (SF-12) PROMs were identified and included in the systematic review. EPIC and EORTC QLQ-C30, a general module that assesses patients' physical, psychological, and social functions, were characterised by high internal consistency (Cronbach's alpha 0.46-0.96 and 0.68-0.94 respectively) but low content validity. EORTC QLQ-PR25, which is primarily designed to assess PCa-specific HRQoL, had moderate content validity and internal consistency (Cronbach's alpha 0.39-0.87). UCLA-PCI was characterised by moderate content validity and high internal consistency (Cronbach's alpha 0.21-0.94). However, it does not directly assess hormonal symptoms, whereas EORTC QLQ-PR25 does. CONCLUSION: The tools with the best evidence for psychometric properties and feasibility for use in routine practice and research settings to assess PROMs in patients with localised PCa were EORTC QLQ-C30 and QLQ-PR25. Since EORTC QLQ-C30 is a general module that does not directly assess PCa-specific issues, it should be adopted in conjunction with the QLQ-PR25 module. PATIENT SUMMARY: We reviewed and appraised the measurement properties of patient-reported outcome measure questionnaires used for patients with localised prostate cancer. We found good evidence to suggest that two questionnaires (EORTC QLQ-C30 and QLQ-PR25) can be used to measure urinary, bowel, and sexual functions and health-related quality of life.
- Full Text
- View/download PDF
45. A0852 - Development of prostate cancer typical case presentations and their usage in OPTIMA's guideline based decision support tool.
- Author
-
Murray, C., Beyer, K., Gandaglia, G., Stabile, A., Auweter, S., Morariu, A., Santiago, I., Maclennan, S., Thomas, M., Bjartell, A., Cornford, P., Kruger, H., N'dow, J., Roobol, M., and Omar, M.I.
- Subjects
- *
CARCINOGENESIS , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
46. P250 - Assessing the impact and timing of salvage radiation therapy in men with biochemically recurrent prostate cancer after radical prostatectomy and negative PSMA PET.
- Author
-
Cannoletta, D., Mazzone, E., Gandaglia, G., Stabile, A., Cucchiara, V., Picchio, M., Cozzarini, C., Chiti, A., Scilipoti, P., Longoni, M., Sorce, G., Pellegrino, F., Cirulli, G.O., Robesti, D., Leni, R., Quarta, L., Necchi, A., Raggi, A., Montorsi, F., and Briganti, A.
- Subjects
- *
RADICAL prostatectomy , *SALVAGE therapy , *RADIOTHERAPY , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
47. SC168 - Which patients with clinically node positive prostate cancer should be considered as candidates for radical prostatectomy as part of a multimodal treatment? The impact of nodal burden.
- Author
-
Robesti, D., Gandaglia, G., Karnes, R., Devos, G., Battaglia, A., Muilwijk, T., Soligo, M., Everaerts, W., Boeri, L., Scuderi, S., Stabile, A., Dell' Oglio, P., Bandini, M., Fossati, N., Moschini, M., Joniau, S., Montorsi, F., and Briganti, A.
- Subjects
- *
COMBINED modality therapy , *PROSTATE cancer - Published
- 2019
- Full Text
- View/download PDF
48. SC39 - Development of novel criteria for active surveillance based on multiparametric MRI alone in men with Gleason 3 + 4 prostate cancer: Use of imaging to safely expand the eligibility for active surveillance.
- Author
-
Briganti, A., Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J., Malavaud, B., Roumiguié, M., Dell'Oglio, P., Suardi, N., Moschini, M., Zamboni, S., Rakauskas, A., Mirone, V., De Cobelli, F., Porpiglia, F., and Montorsi, F.
- Subjects
- *
PROSTATE cancer , *IMAGING of cancer - Published
- 2019
- Full Text
- View/download PDF
49. 589 - Which positive surgical margins features impact on the risk of prostate cancer specific mortality? A disease-tailored, competing-risk, long-term analysis.
- Author
-
Suardi, N., Gandaglia, G., Robesti, D., Scuderi, S., Barletta, F., Dell'Oglio, P., Mazzone, E., Bandini, M., Freschi, M., Stabile, A., Zaffuto, E., Mirone, V., Longo, N., Shariat, S.F., Soria, F., D'Andrea, D., Luciano', R., Capitanio, U., Fossati, N., and Montorsi, F.
- Subjects
- *
CANCER-related mortality , *SURGICAL site , *PROSTATE cancer - Published
- 2019
- Full Text
- View/download PDF
50. P046 - The role of artificial intelligence for the detection of clinically significant prostate cancer at multiparametric magnetic resonance imaging.
- Author
-
Quarta, L., Scuderi, S., Gandaglia, G., Stabile, A., Marzorati, C., Russo, T., Brembilla, G., Camisassa, E., Leni, R., Cucchiara, V., Bianchi, M., Cannoletta, D., Zaurito, P., Barletta, F., Cosenza, M., Robesti, D., Mazzone, E., De Cobelli, F., Montorsi, F., and Briganti, A.
- Subjects
- *
MAGNETIC resonance imaging , *ARTIFICIAL intelligence , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.